Ashwini Gore, MD
Endocrinology, Diabetes & Metabolism · Macon, GANPI 1457373565
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.0%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. It is spread thinly across 59 manufacturers, the largest accounting for just 21.3%. Reporting peaked in 2019 at $18,261 and has fallen 80.5% since, to $3,557 in 2025. Among endocrinology, diabetes & metabolism clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 934 payments — averaging $36.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$7K
- Merck$7K
- Johnson & Johnson$3K
- Amgen$2K
- AstraZeneca$2K
- Tandem Diabetes Care, Inc.$2K
- plus $11K from 53 others
Across 666 payments — averaging $3821.83 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$828K
- Boehringer Ingelheim International GmbH$289K
- Boehringer Ingelheim Pharma GmbH & Co.kg$274K
- Astrazeneca UK Limited$228K
- Bayer$200K
- Boehringer Ingelheim$200K
- plus $527K from 6 others
What the payments were for
- Consulting fees$5,75517%
- Speaking & faculty fees$9,27527%
- Travel & lodging$1,6285%
- Food & beverage$17,52651%
- Education$880%
- Gifts$590%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STEGLATRO$6,218
- Victoza$5,227
- INVOKANA$2,571
- t-slim insulin pump$750
- t:slim X2 insulin pump$701
- EVENITY$497
- JATENZO$330
- UNITY DIABETES MANAGEMENT SYSTEM$294
- MINIMED 780G$249
- GVOKE PFS$233
- QSYMIA$125
- FARXIGA$125
- Repatha$123
- RYBELSUS$114
- LENVIMA$109
How this compares
$34,332 in reported general payments places this provider in the 90th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
See all endocrinology, diabetes & metabolism providers in Georgia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 296 | $491,260 |
| MounjaroTirzepatide | 216 | $325,229 |
| JardianceEmpagliflozin | 98 | $122,490 |
| TrulicityDulaglutide | 46 | $93,919 |
| Tresiba Flextouch U-200Insulin Degludec | 67 | $93,601 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 55 | $78,611 |
| FarxigaDapagliflozin Propanediol | 48 | $71,950 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 45 | $53,756 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 28 | $53,627 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 44 | $53,073 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 34 | $42,940 |
| Tresiba Flextouch U-100Insulin Degludec | 54 | $38,128 |
| JanuviaSitagliptin Phosphate | 31 | $33,040 |
| ProliaDenosumab | 18 | $31,380 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 38 | $30,691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $7,303 | $520,935330 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $1,472 | $431,931297 claims |
| Boehringer IngelheimJardiance, Synjardy Xr, Trijardy Xr, Tradjenta, Synjardy | $425 | $253,581204 claims |
| AstraZenecaFarxiga | $2,139 | $71,95048 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus | $946 | $54,97256 claims |
| MerckJanuvia | $6,681 | $33,04031 claims |
| AmgenProlia | $2,219 | $31,38018 claims |
| AbbVieSynthroid, Armour Thyroid | $251 | $25,622276 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium, Unithroid | $438 | $8,709524 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 222 endocrinology, diabetes & metabolism providers in Georgia.
Other endocrinology, diabetes & metabolism in Macon
- Barry JohnsMacon$335K
- Thomas JonesMacon$38K
- Bruce BodeAtlanta$1.5M
- David RobertsonAtlanta$1.4M
- Adeniyi OdugbesanLawrenceville$636K
- Miguel MunozMarietta$476K
- Jason BernerJasper$457K
- Dawn Smiley-ByrdTaylorsville$385K
- Jonathan OwnbyAtlanta$291K
- Ismary DecastroSavannah$169K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.